about
HIPK2 inhibits both MDM2 gene and protein by, respectively, p53-dependent and independent regulations.SLC25A1, or CIC, is a novel transcriptional target of mutant p53 and a negative tumor prognostic markerZinc downregulates HIF-1α and inhibits its activity in tumor cells in vitro and in vivoHomeodomain-interacting protein kinase-2 phosphorylates p53 at Ser 46 and mediates apoptosis.High glucose dephosphorylates serine 46 and inhibits p53 apoptotic activityUnfolded p53 in the pathogenesis of Alzheimer's disease: is HIPK2 the link?HIF-1α antagonizes p53-mediated apoptosis by triggering HIPK2 degradation.JNK and macroautophagy activation by bortezomib has a pro-survival effect in primary effusion lymphoma cells.Targeting MKK3 as a novel anticancer strategy: molecular mechanisms and therapeutical implications.Targeting COX-2/PGE(2) pathway in HIPK2 knockdown cancer cells: impact on dendritic cell maturation.Glucose restriction induces cell death in parental but not in homeodomain-interacting protein kinase 2-depleted RKO colon cancer cells: molecular mechanisms and implications for tumor therapyHSP70 inhibition by 2-phenylethynesulfonamide induces lysosomal cathepsin D release and immunogenic cell death in primary effusion lymphoma.Reactivation of mutant p53 by capsaicin, the major constituent of peppersZinc supplementation is required for the cytotoxic and immunogenic effects of chemotherapy in chemoresistant p53-functionally deficient cells.ZnCl2 sustains the adriamycin-induced cell death inhibited by high glucose.Kaposi sarcoma associated herpesvirus (KSHV) induces AKT hyperphosphorylation, bortezomib-resistance and GLUT-1 plasma membrane exposure in THP-1 monocytic cell line.Hyperglycemia triggers HIPK2 protein degradation.HIPK2-a therapeutical target to be (re)activated for tumor suppression: role in p53 activation and HIF-1α inhibition.Regulation of p53 activity by HIPK2: molecular mechanisms and therapeutical implications in human cancer cells.Mutant p53 proteins alter cancer cell secretome and tumour microenvironment: Involvement in cancer invasion and metastasis.HIPK2 downregulates vimentin and inhibits breast cancer cell invasion.Restoring p53 active conformation by zinc increases the response of mutant p53 tumor cells to anticancer drugs.Nox1 is involved in p53 deacetylation and suppression of its transcriptional activity and apoptosis.Inhibition of HIF-1alpha activity by homeodomain-interacting protein kinase-2 correlates with sensitization of chemoresistant cells to undergo apoptosis.Restoring wtp53 activity in HIPK2 depleted MCF7 cells by modulating metallothionein and zinc.Oxidant species are involved in T/B-mediated ERK1/2 phosphorylation that activates p53-p21 axis to promote KSHV lytic cycle in PEL cells.HIPK2 knock-down compromises tumor cell efficiency to repair damaged DNA.Homeodomain-interacting protein kinase-2 restrains cytosolic phospholipase A2-dependent prostaglandin E2 generation in human colorectal cancer cells.Quercetin induces apoptosis and autophagy in primary effusion lymphoma cells by inhibiting PI3K/AKT/mTOR and STAT3 signaling pathways.Concomitant reduction of c-Myc expression and PI3K/AKT/mTOR signaling by quercetin induces a strong cytotoxic effect against Burkitt's Lymphoma.N(6)-Methyldeoxyadenosine, a nucleoside commonly found in prokaryotes, induces C2C12 myogenic differentiation.High glucose and hyperglycemic sera from type 2 diabetic patients impair DC differentiation by inducing ROS and activating Wnt/β-catenin and p38 MAPK.p53-Dependent PUMA to DRAM antagonistic interplay as a key molecular switch in cell-fate decision in normal/high glucose conditionsMetformin triggers apoptosis in PEL cells and alters bortezomib-induced Unfolded Protein Response increasing its cytotoxicity and inhibiting KSHV lytic cycle activation.Apigenin, by activating p53 and inhibiting STAT3, modulates the balance between pro-apoptotic and pro-survival pathways to induce PEL cell death.Chloroquine supplementation increases the cytotoxic effect of curcumin against Her2/neu overexpressing breast cancer cells in vitro and in vivo in nude mice while counteracts it in immune competent mice.Type IV collagenase(s) and TIMPs modulate endothelial cell morphogenesis in vitro.The 72-kDa and the 92-kDa gelatinases, but not their inhibitors TIMP-1 and TIMP-2, are expressed in early psoriatic lesions.Histone deacetylase inhibitors VPA and TSA induce apoptosis and autophagy in pancreatic cancer cells.Zinc supplementation augments in vivo antitumor effect of chemotherapy by restoring p53 function.
P50
Q33292477-90346729-E841-4F81-8FD6-342949BE177DQ33576879-7F103235-0AA5-4A35-9363-77A251E6FA8FQ33778211-73CBAFB5-56A9-4A0C-9464-5F0E43DDA595Q34108288-FFA9C4B1-AA71-4E5A-89EE-9045CADC01D9Q34274477-B6743B50-2049-4804-91A9-68739C5991C0Q34322386-AD4EF1CB-BAB6-4E63-8FFF-49BF88BE8B20Q34616703-A384D688-E74D-47CC-82CB-22EB291DDC9EQ35006105-0B3A8606-E7DB-4348-B484-58017B6AFCD0Q36347205-C1045402-28A0-40CD-8086-753484023142Q36380799-BD1F9139-80C9-4F35-8521-389BD0F01845Q36907145-62CD4103-FF6F-485F-8438-306075B64E78Q37062084-E2ABBC78-BABC-4BD8-A5B0-5159731C094AQ37233582-AFBDCBC0-3652-4056-87CB-4AFAE6F286B3Q37289086-FD3D98B8-04C1-43E7-A928-0AD5A8CBE99FQ37412531-34E30233-9188-4920-9730-9EA964D99996Q37418380-122816E8-FFA1-4C6F-99E4-16D24E1A1726Q37702069-E01D4012-73BC-4F2C-944C-8AF2F0881117Q37710294-69B677FC-8533-4720-830A-BEC0F753F65CQ37761824-8C50E12A-1F70-4C1F-A555-498AC6C8A209Q38798376-C1FCF5F9-44B1-452E-AAC0-0355C052E8FBQ39413701-78FB1372-9026-43FB-9BCF-E6F857487BF6Q39555392-57A8BC76-74DF-4262-8A36-2E432D78AF89Q39737137-307BF8A8-E29D-42CD-AAE0-4754546571E2Q39898008-707CA914-6EA2-475A-BA80-E77D874134C3Q39919668-49CC6C4C-A236-48C0-A03A-3C30EDC262A5Q40085660-59DDDF1C-82AA-4B2A-AC1C-44FC381F6E01Q40101549-B38DF34E-463F-4FF7-8EB8-715A9C5026BEQ40318946-90870AF0-619E-451D-A073-32D404438061Q40378883-E2634183-C4F8-4E46-8C82-28C3D3CA70B7Q40543100-D591DA00-1FFA-45DC-9752-021CD6607D79Q40597569-467935F4-2121-49A8-9449-BF1298EEEE38Q40832486-776DAA2C-9E74-40F3-826B-0AFDAA73DE49Q41279239-9BD402EF-6F68-40A8-BDD9-B9F6AA311815Q41927299-39A4A334-E8D5-4BB5-8345-0BA7CF5E6D9CQ47105497-AA86442D-E88C-489D-8665-E929F9412E0DQ51783558-651F3E19-4573-4160-AB75-DD6330742C28Q52223671-F2F2EBA4-6DF0-4AF3-A1EF-69570C83A31EQ52528530-A527CFBC-A9E2-40CA-B0AE-D908BD5D8B76Q52795326-BF9560F3-77CB-456F-9632-013663DDC57CQ54348087-C786A4AA-8B1B-41F2-A8F3-4AE378ECF842